Compare XHR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | OLMA |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2014 | 2020 |
| Metric | XHR | OLMA |
|---|---|---|
| Price | $16.30 | $16.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.20 | ★ $44.89 |
| AVG Volume (30 Days) | 507.6K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 326.67 | 15.00 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $1,078,500,000.00 | N/A |
| Revenue This Year | $4.13 | N/A |
| Revenue Next Year | $3.29 | N/A |
| P/E Ratio | $25.14 | ★ N/A |
| Revenue Growth | ★ 3.80 | N/A |
| 52 Week Low | $9.61 | $3.89 |
| 52 Week High | $16.48 | $36.26 |
| Indicator | XHR | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 48.08 |
| Support Level | $14.26 | $13.11 |
| Resistance Level | $16.35 | $27.38 |
| Average True Range (ATR) | 0.36 | 0.79 |
| MACD | 0.19 | 0.56 |
| Stochastic Oscillator | 98.94 | 81.22 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.